TY - JOUR
T1 - Perioperative ketorolac in high risk breast cancer patients
T2 - Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial
AU - Forget, Patrice
AU - Berlière, Martine
AU - van Maanen, Aline
AU - Duhoux, Francois P.
AU - Machiels, Jean-Pascal
AU - Coulie, Pierre G.
AU - Bouche, Gauthier
AU - De Kock, Marc
AU - Ketorolac in Breast Cancer trial (KBCtrial) group
N1 - Financial support
This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Université catholique de Louvain, St-Luc Hospital.
PY - 2013/10
Y1 - 2013/10
N2 - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
AB - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84883765692&partnerID=MN8TOARS
U2 - 10.1016/j.mehy.2013.07.033
DO - 10.1016/j.mehy.2013.07.033
M3 - Article
VL - 81
SP - 707
EP - 712
JO - Medical Hypotheses
JF - Medical Hypotheses
SN - 0306-9877
IS - 4
ER -
